S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Relay Therapeutics (RLAY) Stock Price, News & Analysis

$6.83
-0.20 (-2.84%)
(As of 04/15/2024 ET)
Today's Range
$6.70
$7.16
50-Day Range
$6.83
$10.84
52-Week Range
$5.95
$18.32
Volume
715,040 shs
Average Volume
1.10 million shs
Market Capitalization
$895.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.69

Relay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
246.8% Upside
$23.69 Price Target
Short Interest
Bearish
8.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.06mentions of Relay Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$43,814 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.84) to ($2.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

495th out of 929 stocks

Biological Products, Except Diagnostic Industry

80th out of 149 stocks

RLAY stock logo

About Relay Therapeutics Stock (NASDAQ:RLAY)

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Stock Price History

RLAY Stock News Headlines

A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
RLAY Apr 2024 7.500 call
RLAY Apr 2024 7.500 put
A.I. “Perfect Storm” Could Send THESE Stocks Sky High
A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.
Relay Therapeutics (NASDAQ: RLAY)
Relay Therapeutics's Earnings: A Preview
Relay Therapeutics Inc (RLAY)
RLAY Mar 2024 7.500 put
VERV Mar 2024 12.500 call
See More Headlines
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/15/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RLAY
Fax
N/A
Employees
323
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.69
High Stock Price Target
$33.00
Low Stock Price Target
$12.50
Potential Upside/Downside
+246.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-341,970,000.00
Net Margins
-1,263.49%
Pretax Margin
-1,338.66%

Debt

Sales & Book Value

Annual Sales
$25.55 million
Book Value
$5.90 per share

Miscellaneous

Free Float
126,535,000
Market Cap
$895.96 million
Optionable
Optionable
Beta
1.63
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives


RLAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RLAY shares.
View RLAY analyst ratings
or view top-rated stocks.

What is Relay Therapeutics' stock price target for 2024?

10 brokerages have issued 1-year target prices for Relay Therapeutics' shares. Their RLAY share price targets range from $12.50 to $33.00. On average, they expect the company's share price to reach $23.69 in the next year. This suggests a possible upside of 246.8% from the stock's current price.
View analysts price targets for RLAY
or view top-rated stocks among Wall Street analysts.

How have RLAY shares performed in 2024?

Relay Therapeutics' stock was trading at $11.01 at the start of the year. Since then, RLAY stock has decreased by 38.0% and is now trading at $6.83.
View the best growth stocks for 2024 here
.

When is Relay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RLAY earnings forecast
.

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its earnings results on Thursday, February, 22nd. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.09. Relay Therapeutics had a negative trailing twelve-month return on equity of 42.43% and a negative net margin of 1,263.49%. During the same period in the previous year, the company earned ($0.56) EPS.

What ETFs hold Relay Therapeutics' stock?

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI) and TrueShares Technology, AI & Deep Learning ETF (LRNZ).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).

When did Relay Therapeutics IPO?

Relay Therapeutics (RLAY) raised $250 million in an initial public offering on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.11%), TrueMark Investments LLC (0.04%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Sanjiv Patel and Thomas Catinazzo.
View institutional ownership trends
.

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLAY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners